Our Latest News - BUHLMANN

BUHLMANN News

Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®

BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®.  CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Continue Reading

Connect with BUHLMANN at AAAAI 2018

  AAAAI 2018 AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY BUHLMANN Diagnostics Corp  Booth: #133 March 3 - 5, 2018 | Orange County Convention Center | Orlando, FL Learn More Come by our booth to connect with our team and discuss peanut allergy BAT testing & more! BÜHLMANN offers broad range of quality controlled allergens and mixes
Continue Reading

Clinical Applications of the Basophil Activation Test in Food Allergy

Download eBOOK Webinar Recording Webinar Overview Abstract The basophil activation test has emerged as a novel diagnostic test for food allergy. Being a functional test, it has the potential to closely resemble the clinical phenotype of patients following allergen exposure. The basophil activation test can be seen as an in vitro challenge, where instead of
Continue Reading

Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: A.Kostas, S.I. Siakavellas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a
Continue Reading

Évaluation du test BÜHLMANN fCAL® turbo au City Hospital Triemli de Zurich

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 English Version ENTRETIEN AVEC ANITA GRÜNAUER ET PREDRAG NESIC, Hôpital municipal de Zurich, Triemli Madame Grünauer, Monsieur Nesic, votre équipe du laboratoire de chimie clinique de l’hôpital de Triemli a décidé d’utiliser le test
Continue Reading

Evaluation of the BÜHLMANN fCAL® turbo Test at City Hospital Triemli in Zurich

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 French Version INTERVIEW WITH ANITA GRÜNAUER AND PREDRAG NESIC, City Hospital Triemli, Zurich Mrs. Grünauer and Mr. Nesic, several months ago you decided to implement the BÜHLMANN fCAL® turbo on your Roche cobas® c501 system. Can
Continue Reading

On Board with fCAL® turbo at Cumberland Infirmary

Pamela Bowe loads BÜHLMANN fCAL® turbo faecal calprotectin tests onto the Roche cobas® 6000 c501 analyser BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Pamela Bowe, Team Manager in the Department of Biochemistry at the Cumberland Infirmary tells us about her experience
Continue Reading

Bringing Calprotectin Testing In-house on the Abbott Architect C8000

Mary O'Connell nee Deasy, Mercy University Hospital BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Mary O'Connell nee Deasy, Biochemistry Department, Mercy University Hospital Cork, Ireland introduces Faecal Calprotectin testing into their laboratory using the BÜHLMANN fCAL® turbo assay. At the Biochemistry
Continue Reading

BUHLMANN LabSense News: Fall 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the fifth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. You won’t want to miss some interesting highlights for the Flow CAST® assay including interesting videos, ebooks and more in this edition! Check Out LabSense News Today! VIEW
Continue Reading

Exploration of Predictive Biomarkers of Early IFX Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early IFX response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading